RT Journal Article
SR Electronic
T1 The effect of sample medication use on subsequent anti-VEGF agent selection for neovascular age-related macular degeneration
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.27.21261104
DO 10.1101/2021.07.27.21261104
A1 Karen M. Wai
A1 Tedi Begaj
A1 Sachi Patil
A1 Evan Chen
A1 John B. Miller
A1 Jan Kylstra
A1 Mary E. Aronow
A1 Lucy H. Young
A1 Rachel Huckfeldt
A1 Deeba Husain
A1 Leo A. Kim
A1 Demetrios G. Vavvas
A1 Dean Eliott
A1 Shizuo Mukai
A1 Evangelos S. Gragoudas
A1 Nimesh A. Patel
A1 Lucia Sobrin
A1 Joan W. Miller
A1 Ravi Parikh
A1 David M. Wu
YR 2021
UL http://medrxiv.org/content/early/2021/07/30/2021.07.27.21261104.abstract
AB Purpose To examine the effect of medication sample use (ranibizumab or aflibercept) on future anti-vascular endothelial growth factor (VEGF) agent selection in neovascular age-related macular degeneration (nvAMD).Design Retrospective cohort study.Methods nvAMD patients who underwent an initial anti-VEGF injection with a sample medication were compared to nvAMD control patients who never received a medication sample. Charts from 2017 through 2020 were reviewed for data regarding demographics, anti-VEGF agent selection, and visual acuity outcomes for both groups. Anti-VEGF agent selection for the first four injections and at one year were examined in both the sample and control groups.Results Adherence to the initial agent was high between first and subsequent injections (2nd, 3rd, 4th injection, and 1 year) in both sample (96.2%, 95.9%, 91.9%, 93.4%, respectively) and control groups (98.1%, 94.2%, 94.9%, 87.8%, respectively). Bevacizumab usage was significantly lower among eyes receiving samples relative to controls at the second (1.9% vs. 38.7%, p<0.001), third (3.1% vs. 41.3%, p<0.001), fourth injections (4.7% vs. 40.4%, p<0.001), and at 1 year (0% vs. 33.8%, p<0.001). Aflibercept usage was significantly higher in sample eyes relative to controls at the second (78.3% vs. 43.4%, p<0.001), third (76.3% vs. 41.5%, p<0.001), and fourth injections (76.7% vs. 43.4%, p<0.001), and at 1 year (77.0% vs. 52.7%, p<0.001).Conclusions Eyes receiving a sample anti-VEGF agent (ranibizumab or aflibercept) for their initial injection were less likely to receive bevacizumab at future visits relative to eyes that did not receive an anti-VEGF sample, even after one year of treatment.Competing Interest Statement1. JBM is a consultant for Alcon, Allergan, Carl Zeiss, Sunovion, and Genentech. 2. DH is a consultant for Allergan, Genentech, Omeicos Ophthalmics, and has received financial support from Lions VisionGift, Commonwealth Grant, and Macular Society. 3. LAK has received financial support from National Eye Institute and CureVac AG, has financial arrangement with Pykus Therapeutics, and holds patents through Massachusetts Eye and Ear. 4. DGV is a consultant for Valitor, Olix Pharmaceuticals, and has received financial support from National Eye Institute, Research to Prevent Blindness, Loefflers Family Foundation, Yeatts Family Foundation, and Alcon Research Institute. 5. DE is a consultant for Alcon, Allergan, Dutch Ophthalmics, Genentech, and Glaukos. He has a financial relationship with Alderya Therapeutics and Pykus Therapeutics, and has received financial support from Neurotech Pharmaceuticals. 6. ESG has a financial relationship with Auro Biosciences, Astellas Pharma, and Valeant Pharmaceuticals. 7. JWM is a consultant for Genentech/Roche, KalVista Pharmaceuticals, Ltd., Sunovion, Heidelberg Engineering, LifeBiosciences, Inc; has received financial support from Lowy Medical Research Institute, Ltd.; has royalties with Valeant Pharmaceuticals/Mass Eye and Ear, ONL Therapeutics, LLC; Aptinyx, Inc; and holds a patent through Valeant Pharmaceuticals/Mass Eye and Ear, ONL Therapeutics, LLC. 8. DMW holds a patent through Massachusetts Eye and Ear. 9. RP was a consultant for Anthem Blue Cross and Blue Shield. 10. All other authors (KMW, TB, SP, EC, JK, MEA, LHH, RH, SM, NAP, LS) have reported that they have no relationships relevant to the contents of this paper to disclose. Funding StatementThere is no funding support to report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the institutional review board of the Massachusetts General Hospital and Partners Healthcare (IRB # 2021P000301) and is compliant with the Declaration of Helsinki and Health Insurance Portability and Accountability Act regulations.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request.